Last reviewed 2026-04-19 · How we verify

ABT-925

discontinued Small molecule

ABT-925 is an experimental drug studied in people with worsening schizophrenia to see if it is safe and effective.

ABT-925 is an investigational compound that was evaluated in a Phase 2 trial for acute exacerbation of schizophrenia, with 156 subjects enrolled to assess safety and efficacy.

At a glance

Generic name	ABT-925
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	discontinued

Mechanism of action

ABT-925 is a drug that was being studied to help people who are experiencing a sudden worsening of schizophrenia symptoms. Schizophrenia is a condition where people may have trouble thinking clearly, feeling emotions normally, or relating to others. When symptoms get worse quickly, it is called an acute exacerbation. Researchers wanted to see if ABT-925 could help improve these symptoms and be safe for people to take during such times.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia (Phase 2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ABT-925 CI brief — competitive landscape report
ABT-925 updates RSS · CI watch RSS
portfolio CI